SGK ||| S:0 E:3 ||| NNP
,  ||| S:3 E:5 ||| ,
renal  ||| S:5 E:11 ||| JJ
function  ||| S:11 E:20 ||| NN
and  ||| S:20 E:24 ||| CC
hypertension  ||| S:24 E:37 ||| JJ
Serum-  ||| S:37 E:44 ||| JJ
and  ||| S:44 E:48 ||| CC
glucocorticoid-inducible  ||| S:48 E:73 ||| JJ
kinase  ||| S:73 E:80 ||| NN
1  ||| S:80 E:82 ||| CD
( ||| S:82 E:83 ||| -LRB-
SGK1 ||| S:83 E:87 ||| NNP
)  ||| S:87 E:89 ||| -RRB-
is  ||| S:89 E:92 ||| VBZ
expressed  ||| S:92 E:102 ||| VBN
following  ||| S:102 E:112 ||| VBG
cell  ||| S:112 E:117 ||| NN
stress  ||| S:117 E:124 ||| NN
and  ||| S:124 E:128 ||| CC
exposure  ||| S:128 E:137 ||| NN
to  ||| S:137 E:140 ||| TO
a  ||| S:140 E:142 ||| DT
variety  ||| S:142 E:150 ||| NN
of  ||| S:150 E:153 ||| IN
hormones  ||| S:153 E:162 ||| NNS
including  ||| S:162 E:172 ||| VBG
glucocorticoids  ||| S:172 E:188 ||| NNS
and  ||| S:188 E:192 ||| CC
mineralocorticoids ||| S:192 E:210 ||| NN
.  ||| S:210 E:212 ||| .
It  ||| S:212 E:215 ||| PRP
is  ||| S:215 E:218 ||| VBZ
activated  ||| S:218 E:228 ||| VBN
by  ||| S:228 E:231 ||| IN
insulin  ||| S:231 E:239 ||| NN
and  ||| S:239 E:243 ||| CC
growth  ||| S:243 E:250 ||| NN
factors  ||| S:250 E:258 ||| NNS
via  ||| S:258 E:262 ||| IN
phosphatidylinositol-3-kinase  ||| S:262 E:292 ||| NNP
and  ||| S:292 E:296 ||| CC
the  ||| S:296 E:300 ||| DT
3-phosphoinositide-dependent  ||| S:300 E:329 ||| CD
kinase  ||| S:329 E:336 ||| CD
PDK1 ||| S:336 E:340 ||| CD
.  ||| S:340 E:342 ||| .
SGK1  ||| S:342 E:347 ||| NNP
enhances  ||| S:347 E:356 ||| VBZ
the  ||| S:356 E:360 ||| DT
activity  ||| S:360 E:369 ||| NN
of  ||| S:369 E:372 ||| IN
a  ||| S:372 E:374 ||| DT
variety  ||| S:374 E:382 ||| NN
of  ||| S:382 E:385 ||| IN
ion  ||| S:385 E:389 ||| JJ
channels  ||| S:389 E:398 ||| NNS
such  ||| S:398 E:403 ||| JJ
as  ||| S:403 E:406 ||| IN
ENaC ||| S:406 E:410 ||| NNP
,  ||| S:410 E:412 ||| ,
TRPV5 ||| S:412 E:417 ||| NNP
,  ||| S:417 E:419 ||| ,
ROMK ||| S:419 E:423 ||| NNP
,  ||| S:423 E:425 ||| ,
KCNE1 ||| S:425 E:430 ||| NNP
/ ||| S:430 E:431 ||| NNP
KCNQ1  ||| S:431 E:437 ||| NNP
and  ||| S:437 E:441 ||| CC
ClCKb ||| S:441 E:446 ||| JJ
;  ||| S:446 E:448 ||| :
carriers  ||| S:448 E:457 ||| NNS
such  ||| S:457 E:462 ||| JJ
as  ||| S:462 E:465 ||| IN
NHE3 ||| S:465 E:469 ||| NNP
,  ||| S:469 E:471 ||| ,
NKCC2 ||| S:471 E:476 ||| NNP
,  ||| S:476 E:478 ||| ,
NCC  ||| S:478 E:482 ||| NNP
and  ||| S:482 E:486 ||| CC
SGLT1 ||| S:486 E:491 ||| NNP
;  ||| S:491 E:493 ||| :
as  ||| S:493 E:496 ||| RB
well  ||| S:496 E:501 ||| RB
as  ||| S:501 E:504 ||| IN
the  ||| S:504 E:508 ||| DT
Na+ ||| S:508 E:511 ||| CD
/ ||| S:511 E:512 ||| CD
K+-ATPase ||| S:512 E:521 ||| CD
.  ||| S:521 E:523 ||| .
SGK1  ||| S:523 E:528 ||| NNP
contributes  ||| S:528 E:540 ||| VBZ
to  ||| S:540 E:543 ||| TO
Na+  ||| S:543 E:547 ||| CD
retention  ||| S:547 E:557 ||| NN
and  ||| S:557 E:561 ||| CC
K+  ||| S:561 E:564 ||| CD
elimination  ||| S:564 E:576 ||| NN
of  ||| S:576 E:579 ||| IN
the  ||| S:579 E:583 ||| DT
kidney  ||| S:583 E:590 ||| NN
as  ||| S:590 E:593 ||| IN
well  ||| S:593 E:598 ||| RB
as  ||| S:598 E:601 ||| IN
mineralocorticoid  ||| S:601 E:619 ||| JJ
stimulation  ||| S:619 E:631 ||| NN
of  ||| S:631 E:634 ||| IN
salt  ||| S:634 E:639 ||| JJ
appetite ||| S:639 E:647 ||| NN
.  ||| S:647 E:649 ||| .
A  ||| S:649 E:651 ||| DT
certain  ||| S:651 E:659 ||| JJ
SGK1  ||| S:659 E:664 ||| CD
gene  ||| S:664 E:669 ||| NN
variant  ||| S:669 E:677 ||| NNS
( ||| S:677 E:678 ||| -LRB-
combined  ||| S:678 E:687 ||| JJ
polymorphisms  ||| S:687 E:701 ||| NN
in  ||| S:701 E:704 ||| IN
intron  ||| S:704 E:711 ||| CD
6  ||| S:711 E:713 ||| CD
[ ||| S:713 E:714 ||| -LRB-
I6CC ||| S:714 E:718 ||| NNP
]  ||| S:718 E:720 ||| -RRB-
and  ||| S:720 E:724 ||| CC
in  ||| S:724 E:727 ||| IN
exon  ||| S:727 E:732 ||| CD
8  ||| S:732 E:734 ||| CD
[ ||| S:734 E:735 ||| -LRB-
E8CC ||| S:735 E:739 ||| NNP
/ ||| S:739 E:740 ||| NNP
CT ||| S:740 E:742 ||| NNP
] ||| S:742 E:743 ||| -RRB-
)  ||| S:743 E:745 ||| -RRB-
is  ||| S:745 E:748 ||| VBZ
associated  ||| S:748 E:759 ||| VBN
with  ||| S:759 E:764 ||| IN
moderately  ||| S:764 E:775 ||| RB
enhanced  ||| S:775 E:784 ||| JJ
blood  ||| S:784 E:790 ||| NN
pressure ||| S:790 E:798 ||| NN
.  ||| S:798 E:800 ||| .
The  ||| S:800 E:804 ||| DT
SGK1  ||| S:804 E:809 ||| JJ
gene  ||| S:809 E:814 ||| NN
variant  ||| S:814 E:822 ||| NN
has  ||| S:822 E:826 ||| VBZ
been  ||| S:826 E:831 ||| VBN
shown  ||| S:831 E:837 ||| VBN
to  ||| S:837 E:840 ||| TO
affect  ||| S:840 E:847 ||| VB
3 ||| S:847 E:848 ||| CD
% ||| S:848 E:849 ||| NN
-5 ||| S:849 E:851 ||| CD
%  ||| S:851 E:853 ||| NN
of  ||| S:853 E:856 ||| IN
whites  ||| S:856 E:863 ||| NNS
and  ||| S:863 E:867 ||| CC
some  ||| S:867 E:872 ||| DT
10 ||| S:872 E:874 ||| CD
%  ||| S:874 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
Africans ||| S:879 E:887 ||| NNP
.  ||| S:887 E:889 ||| .
The  ||| S:889 E:893 ||| DT
gene  ||| S:893 E:898 ||| NN
variant  ||| S:898 E:906 ||| NNS
sensitizes  ||| S:906 E:917 ||| VBP
the  ||| S:917 E:921 ||| DT
carriers  ||| S:921 E:930 ||| NNS
to  ||| S:930 E:933 ||| TO
the  ||| S:933 E:937 ||| DT
hypertensive  ||| S:937 E:950 ||| JJ
effects  ||| S:950 E:958 ||| NNS
of  ||| S:958 E:961 ||| IN
hyperinsulinemia ||| S:961 E:977 ||| NN
.  ||| S:977 E:979 ||| .
Moreover ||| S:979 E:987 ||| RB
,  ||| S:987 E:989 ||| ,
the  ||| S:989 E:993 ||| DT
SGK1  ||| S:993 E:998 ||| JJ
gene  ||| S:998 E:1003 ||| NN
variant  ||| S:1003 E:1011 ||| NN
is  ||| S:1011 E:1014 ||| VBZ
associated  ||| S:1014 E:1025 ||| VBN
with  ||| S:1025 E:1030 ||| IN
increased  ||| S:1030 E:1040 ||| JJ
body  ||| S:1040 E:1045 ||| NN
mass  ||| S:1045 E:1050 ||| NN
index ||| S:1050 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
presumably  ||| S:1057 E:1068 ||| RB
a  ||| S:1068 E:1070 ||| DT
result  ||| S:1070 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
enhanced  ||| S:1080 E:1089 ||| JJ
SGLT1  ||| S:1089 E:1095 ||| CD
activity  ||| S:1095 E:1104 ||| NN
with  ||| S:1104 E:1109 ||| IN
accelerated  ||| S:1109 E:1121 ||| FW
intestinal  ||| S:1121 E:1132 ||| FW
glucose  ||| S:1132 E:1140 ||| FW
absorption ||| S:1140 E:1150 ||| FW
.  ||| S:1150 E:1152 ||| .
Obesity  ||| S:1152 E:1160 ||| NNP
predisposes  ||| S:1160 E:1172 ||| VBD
the  ||| S:1172 E:1176 ||| DT
carriers  ||| S:1176 E:1185 ||| NNS
of  ||| S:1185 E:1188 ||| IN
the  ||| S:1188 E:1192 ||| DT
gene  ||| S:1192 E:1197 ||| NN
variant  ||| S:1197 E:1205 ||| NN
to  ||| S:1205 E:1208 ||| TO
development  ||| S:1208 E:1220 ||| NN
of  ||| S:1220 E:1223 ||| IN
type  ||| S:1223 E:1228 ||| NN
2  ||| S:1228 E:1230 ||| CD
diabetes ||| S:1230 E:1238 ||| NN
.  ||| S:1238 E:1240 ||| .
Moreover ||| S:1240 E:1248 ||| RB
,  ||| S:1248 E:1250 ||| ,
SGK1  ||| S:1250 E:1255 ||| FW
stimulates  ||| S:1255 E:1266 ||| FW
coagulation ||| S:1266 E:1277 ||| FW
.  ||| S:1277 E:1279 ||| .
Thus ||| S:1279 E:1283 ||| RB
,  ||| S:1283 E:1285 ||| ,
SGK1  ||| S:1285 E:1290 ||| NNP
may  ||| S:1290 E:1294 ||| MD
participate  ||| S:1294 E:1306 ||| VB
in  ||| S:1306 E:1309 ||| IN
the  ||| S:1309 E:1313 ||| DT
pathogenesis  ||| S:1313 E:1326 ||| NN
of  ||| S:1326 E:1329 ||| IN
metabolic  ||| S:1329 E:1339 ||| JJ
syndrome  ||| S:1339 E:1348 ||| NN
or  ||| S:1348 E:1351 ||| CC
syndrome  ||| S:1351 E:1360 ||| NN
X ||| S:1360 E:1361 ||| NN
,  ||| S:1361 E:1363 ||| ,
a  ||| S:1363 E:1365 ||| DT
condition  ||| S:1365 E:1375 ||| NN
characterized  ||| S:1375 E:1389 ||| VBN
by  ||| S:1389 E:1392 ||| IN
the  ||| S:1392 E:1396 ||| DT
coincidence  ||| S:1396 E:1408 ||| NN
of  ||| S:1408 E:1411 ||| IN
essential  ||| S:1411 E:1421 ||| JJ
hypertension ||| S:1421 E:1433 ||| NN
,  ||| S:1433 E:1435 ||| ,
procoagulant  ||| S:1435 E:1448 ||| JJ
state ||| S:1448 E:1453 ||| NN
,  ||| S:1453 E:1455 ||| ,
obesity ||| S:1455 E:1462 ||| NN
,  ||| S:1462 E:1464 ||| ,
insulin  ||| S:1464 E:1472 ||| NN
resistance  ||| S:1472 E:1483 ||| NN
and  ||| S:1483 E:1487 ||| CC
hyperinsulinemia ||| S:1487 E:1503 ||| NN
.  ||| S:1503 E:1505 ||| .
